| Literature DB >> 26556723 |
Bahman Delalat1, Vonda C Sheppard2, Soraya Rasi Ghaemi1, Shasha Rao3, Clive A Prestidge3, Gordon McPhee1, Mary-Louise Rogers4, Jacqueline F Donoghue5,6, Vinochani Pillay5,6, Terrance G Johns5,6, Nils Kröger2,7,8, Nicolas H Voelcker1.
Abstract
The ability to selectively kill cancerous cell populations while leaving healthy cells unaffected is a key goal in anticancer therapeutics. The use of nanoporous silica-based materials as drug-delivery vehicles has recently proven successful, yet production of these materials requires costly and toxic chemicals. Here we use diatom microalgae-derived nanoporous biosilica to deliver chemotherapeutic drugs to cancer cells. The diatom Thalassiosira pseudonana is genetically engineered to display an IgG-binding domain of protein G on the biosilica surface, enabling attachment of cell-targeting antibodies. Neuroblastoma and B-lymphoma cells are selectively targeted and killed by biosilica displaying specific antibodies sorbed with drug-loaded nanoparticles. Treatment with the same biosilica leads to tumour growth regression in a subcutaneous mouse xenograft model of neuroblastoma. These data indicate that genetically engineered biosilica frustules may be used as versatile 'backpacks' for the targeted delivery of poorly water-soluble anticancer drugs to tumour sites.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26556723 DOI： 10.1038/ncomms9791
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919